Dec 18 $170 / $180 Bull Call Spread
Buy 1x $170C · Sell 1x $180C · 31d
Updated Nov 19, 2026 5:06 PM ET · Prev Close $168.98
Gilead Sciences Inc (GILD) is trading within a tight intraday band at $166.53 (-1.45%, 0.81x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, GILD is outperforming the S&P 500 by +0.51%. 14-day RSI stands at 55.8, keeping momentum in a bullish regime.
Gilead Sciences reported new clinical and access moves, including positive data for Livdelzi in primary biliary cholangitis and royalty-free licenses for investigational Ebola antiviral obeldesivir across 127 lower incom
Price ($166.53) trades relative to 20-day SMA ($166.80) and 50-day SMA ($156.82).
Compare $16,758 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.3% ATM IV.
Buy 1x $170C · Sell 1x $180C · 31d
Sell 1x $155P · Buy 1x $145P · 31d
Sell 1x $155P · Buy 1x $170/$180C · 31d
Gilead Sciences reported new clinical and access moves, including positive data for Livdelzi in primary biliary cholangitis and royalty-free licenses for investigational Ebola antiviral obeldesivir across 127 lower incom
Today's big story Could Anthropic Stock Fall 25.
Gilead GILD has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The fund added 176.7 million of stock in Monday's session, increasing 233 positions and trimming none.
Monitor volume expansion above 1.5x RVOL around $166.80 (20-day SMA resistance) for directional breakout confirmation.
The latest article discusses Alnylam's $1 billion buyback and its inability to significantly impact the stock price due to market concerns over the growth of Alnylam's main heart drug, Amvuttra. The stock has fallen sharply since its results day, with CEO Yvonne Greenstreet expressing dissatisfaction with the demand growth observed.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing …
Receive an email alert when GILD triggers an unusual volume breakout, options sweep, or rating shift.
Gilead Sciences Inc (GILD) is trading within a tight intraday band at $166.53 (-1.45%, 0.81x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, GILD is outperforming the S&P 500 by +0.51%. 14-day RSI stands at 55.8, keeping momentum in a bullish regime.
Today's session carries a 64% catalyst conviction score on 0.81x relative volume (low participation). Our multi-factor model currently rates GILD as HOLD. Review full valuation, quality, and timing signals on the GILD Buy or Sell Decision Brief →
At $166.53, GILD's modeled 1-to-3 session range is $160.27 – $172.79, with a key inflection level at $166.80 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the GILD Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
RSI at 55.8 reflects constructive bullish momentum. GILD trades at $166.53 relative to its 20-day SMA ($166.80) and 50-day SMA ($156.82), reflecting a bullish moving-average structure.
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.